Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Adenovirus decision: Little fallout seen

Last week's announcement by the Cystic Fibrosis Foundation that it "has suspended recruitment for CF gene therapy studies using the adenovirus vector, until more information on the vector's safety can be obtained", may not have much effect either on trials in CF

Read the full 429 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers